Report Preview

Cluster headache Market

The global cluster headache market size was valued at USD 355 million in 2021 and is projected to reach around USD 610 million in 2030 exhibiting a CAGR of 6.5% in the forecasted period. The rising incidence of cluster headache is expected to upsurge the market growth. Moreover, empowering industrial growth are key players’ continuing research initiatives and launch of new expansions is further assessed to bolster the growth of the cluster headache market. However, the factors such as deficiency of awareness and unfavourable healthcare policies that have a damaging effect on total healthcare expenditure are anticipated to confine the market growth rate.

The rising global elderly population is one of the major factors for the market growth during the forecasted period. As per the World Population Prospects 2019 (United Nations, 2019), by 2050, one in six people will be above the age of 65 worldwide, which will be up from one in 11 people in 2019.

The growing incidences of cluster headache syndrome. As per the latest epidemiological studies, one in 500 people experience cluster headaches. The global cluster headache market is predicted to increase owing to upsurge in number of cluster headache patients with a favourable family history. For instance, as per the study article published by Bio Med Central (BMC) in April 2020, a systematic review and meta-analysis was directed in agreement with the criteria for favoured reporting items for systematic reviews and meta-analysis protocols. With a total I2%-73%, it was discovered that anticipated prevalence of CH patients with a family history was approximately 6.27%.

Pharmaceutical and biotech companies together with administrations across the world are functioning to address the COVID-19 eruption, from assisting the development of vaccines to scheduling for medicine supply chain problems. Presently, about 115 vaccine contenders and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have observed a dramatic growth in demand for the managing COVID-19. Such high request for these drugs has offered huge prospects for manufacturers of COVID-19 controlling drugs, as many established nations are facing deficiency of these drugs. Thus, the pharmaceutical and biotechnology industries are projected to witness a substantial growth in the future, due to the need for vaccine and treatment drugs for COVID-19. This, in turn, is anticipated to have a substantial impact on the cluster headache market.

Drug Type Insights

Among drug type, fast-acting drugs holds a leading position in the global cluster headache market. Anti-inflammatory medications known as corticosteroids, such as prednisone, are fast-acting protective drugs that can be operative for numerous people with cluster headaches.

Type Insights

Based on the type, the cluster headache market is categorized into episodic and chronic. The chronic segment holds the maximum market share during the forecasted period. The chronic type of cluster headache disturbs most patients. The episodic form of the cluster headache may grow over time into the chronic form, or it may be chronic from the start, which boosts the segment’s growth.

Region Insights

In 2021, North America rules the global cluster headache market, owing to innovative healthcare structure alongside the arrival of unconventional technologies to detect the syndrome and the growing prevalence of migraines.

However, Asia Pacific is projected to have the highest growth rate for the forecasted period. This is owing to augmented spending on health infrastructure growth, coupled with an increasing elderly population base.

Key Companies Insights

The market for cluster headache is moderately competitive. With the rising applications of Cluster headache, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the cluster headache market, ultimately boosting the market growth. Some of the key companies working in the global cluster headache market include:

• Zosano Pharma
• Eli Lilly and Company
• Lundbeck Seattle BioPharmaceutical
• Winston Laboratories
• GlaxoSmithKline plc.
• ElectroCore Medical LLC
• Autonomic Technologies, Inc.
• AstraZeneca plc.
• Allergan plc.
• Bayer AG
• Hoffmann-La Roche Ltd
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Sanofi
• AbbVie Inc.
• Other players

Some of the Recent Developments:

• In 2019, Eli Lilly and Company received the approval of Food and Drug Administration on Galcanezumab (Brand Name: Emgality), an antibody used for migraine and cluster headache.
• In 2017, ElectroCore launched gammaCore, a non-invasive vagus nerve stimulator, to treat the acute pain related to episodic cluster headache in adults.

Segments

By Drug Class

• Fast-acting Drugs
• Long-term Drugs
• Short-term Drugs

By Type

• Episodic
• Chronic

By Route of Administration

• Oral
• Topical
• Intravenous
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt